With regards to response to chemotherapy, when 5-FU based adjuvant chemotherapy was administered to stage II and III CRC patients, only those patients with low levels of IGFBP3-methylated tumors were positively affected, resulting in longer DFS and OS times, indicating that the benefit of chemotherapy was limited to this group of CRC patients. Here, IGFBP3 is linked to colorectal carcinoma.